The 'Personalized Treatment for Rare Epileptic Disorders' (PREMED) project receives funding from the Novo Nordisk Foundation

In this project, Kristine Freude will together with her collaborators Rikke Møller Epilepsy center Dianalund and Zeynep Tuemer, Rigshospitalet generate CRISPR-Cas9 knock in induced pluripotent stem cell lines of CACNA1A to model loss and gain of function mutations in rare cases of epilepsy. The neurons generated from those will be tested for various epilepsy drug in order to achieve personalized treatment of epilepsy.